(12) United States Patent (10) Patent No.: US 9.435,817 B2 Benchikh Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO9435817B2 (12) United States Patent (10) Patent No.: US 9.435,817 B2 Benchikh et al. (45) Date of Patent: Sep. 6, 2016 (54) DETECTION OF SYNTHETIC OTHER PUBLICATIONS CANNABINOIDS C. V. Rao, “Immunology. A textbook”. Alpha Science Internatl. Ltd., 2005, pp. 63, 69-71.* (75) Inventors: Elouard Benchikh, Crumlin (GB); Weissman et al., “Cannabimimetic activity from CP-47,497, a Stephen Peter Fitzgerald, Crumlin derivative of 3-phenylcyclohexanol.” J. Pharmacol. Exp. Ther. (GB); Paul John Innocenzi, Crumlin 1982, vol. 223, No. 2, pp. 516-523.* (GB); Philip Andrew Lowry, Crumlin Wild, “The Immunoassay Handbook.” Third Ed., Elsevier, 2005, (GB); Ivan Robert McConnell, pp. 255-256.* Crumlin (GB) Melvin et al., “A cannabinoid derived prototypical analgesic,” J. Med. Chem., 1984, vol. 27, No. 1, pp. 67-71.* Dresen, S. et al., “Monitoring of Herbal Mixtures Potentially (73) Assignee: Randox Laboratories Limited, Containing Synthetic Cannabinoids as Psychoactive Compounds.” Crumlin (GB) J. Mass. Spectrometry, 2010, pp. 1186-1194, vol. 45. Goodrow, M.H. et al., “Strategies for Immunoassay Hapten (*) Notice: Subject to any disclaimer, the term of this Design,” in Immunoanalysis of Agrochemicals; Nelson, J. et al., patent is extended or adjusted under 35 ACS Symposium Series, 1995, Chapter 9, pp. 119-139, vol. 586. U.S.C. 154(b) by 590 days. Hudson, S. et al., “Use of High-Resolution Accurate Mass Spec trometry to Detect Reported and Previously Unreported Can (21) Appl. No.: 13/585,630 nabinomimetics in Herbal High Products,” J. Anal. Toxicol., 2010, pp. 252-260, vol. 34. Huffman, J. et al., “1-Pentyl-3-phenylacetylindoles, a New Class of (22) Filed: Aug. 14, 2012 Cannabimimetic Indoles.” Bioorganic & Medicinal Chemistry Let ters, 2005, pp. 4110-4113, vol. 15. (65) Prior Publication Data Kraemer, T., "V10—Studies on the Metabolism of JWH-18, the US 2013 FOO65323 A1 Mar. 14, 2013 Pharmacologically Active Ingredient of Different Misused Incenses.” Abstracts Vortrage Hauptsymposium, 2008, pp. 90, vol. 76, No. 2. Liu, Y. et al., “Design and Synthesis of AX4697, a Related U.S. Application Data Bisindolylmaleimide Exo-affinity Probe that Labels Protein Kinase C Alpha and Beta,” Bioorganic & Medicinal Chemistry Letters, (63) Continuation-in-part of application No. 13/332,042. 2008, pp. 5955-5958, vol. 18. filed on Dec. 20, 2011, now Pat. No. 8,906,633. Möller, I. et al., “Screening for the Synthetic Cannabinoid JWH-018 and Its Major Metabolities in Human Doping Controls.” Drug (30) Foreign Application Priority Data Testing and Analysis, 2011, pp. 609-620, vol. 3. Rana, S. et al., “Routine Screening of Human Urine for Synthetic Feb. 14, 2011 (GB) ................................... 1102544.2 Cannabinoids by LC-MS/MS Utilizing Spectrum Based Library Jun. 21, 2011 (GB) ................................... 1110425.4 Search.” Redwood Toxicology Laboratory, SOFT 2010. (Abstract). Singh, P. et al., “Synthesis and Evaluation of Indole-based New Scaffolds for Antimicrobial Activities—Identification of Promising (51) Int. Cl. Candidates.” Bioorganic & Medicinal Chemistry Letters, 2011, pp. C07K I6/6 (2006.01) 3367-3372, vol. 21. GOIN 33/94 (2006.01) Sobolevsky, T., “Detection of JWH-018 Metabolites in Smoking C07K I6/44 (2006.01) Mixture Post-Administration Urine.' Forensic Science Interna C07K 7/4 (2006.01) tional, 2010, pp. 141-147, vol. 200. (52) U.S. Cl. Uchiyama, N. et al., “Chemical Analysis of Synthetic Cannabinoids as Designer Drugs in Herbal Products.” Forensic Science Interna CPC ............. G0IN 33/948 (2013.01); C07K 16/44 tional, 2010, pp. 31-38, vol. 198. (2013.01); C07K 17/14 (2013.01) Wintermeyer, A. et al., “In vitro Phase I Metabolism of the Synthetic (58) Field of Classification Search Cannabimimetic JWH-018.” Anal. Bioanal. Chem., 2010, pp. 2141 None 2153, vol. 398. See application file for complete search history. Zhao, D. et al., “Synthesis of Phenol. Aromatic Ether, and Benzofuran Derivatives by Copper-Catalyzed Hydroxylation of (56) References Cited Aryl Halides,” Angew. Chem. Int. Ed., 2009, pp. 8729-8732, vol. 48, Issue 46. U.S. PATENT DOCUMENTS (Continued) 5,248,611 A * 9, 1993 Benkovic et al. ............ 435/28O 5,817,766 A 10, 1998 Hui et al. Primary Examiner — Galina Yakovleva 6,900,236 B1 5/2005 Makriyannis et al. (74) Attorney, Agent, or Firm — Saul Ewing LLP. Kathryn 8,906,633 B2 12/2014 Benchikh et al. 2013/0066053 A1 3/2013 Fitzgerald et al. Doyle; Domingos J. Silva 2013,0196354 A1 8/2013 Fitzgerald et al. 2015.0118763 A1 4/2015 Fitzgerald et al. (57) ABSTRACT The invention describes methods and kits for detecting and FOREIGN PATENT DOCUMENTS determining current and future synthetic cannabinoids from EP O736529 A1 3, 1996 the CP family. Unique antibodies derived from novel immu EP 2487.155 A1 8, 2012 nogens enable said methods and kits. WO O273214 A2 9, 2002 WO 2010 127452 A1 11 2010 2 Claims, 6 Drawing Sheets US 9,435,817 B2 Page 2 (56) References Cited Cannabis Plants and to Investigate New Drug Candidates.” Current Drug Discovery Technologies, (2011) vol. 8, pp. 3-15. Dresen, S., et al., “Development and validation of a liquid chro OTHER PUBLICATIONS matography—tandem mass spectrometry method for the quantita tion of synthetic cannabinoids of the aminoalkylindole type and Randox Toxicology, Product List 2012, pp. 1-43. methanandamide in serum and its application to forensic samples.” Watanabe, K., et al., “Cross-Reactivity of Various Tetrahydrocan J. Mass Spectrom, (2011), vol. 46, pp. 163-171. nabinol Metabolites with a Monoclonal Antibody against Logan, B., et al., “Technical Bulletin: NMS Labs test for JWH-018, Tetrahydrocannabinolic Acid,” Journal of Health Science, (2000), JWH-019, JWH-073, JWH-250 and AM-2201 Primary vol. 46, No. 4, pp. 310-313. Monohydroxy Metabolites in Human Urine.” NMS Labs, (2011), Tanaka, H., et al., “Monoclonal antibody against tetrahydrocan pp. 1-5. nabionolic acid distinguishes Cannabis sativa samples from differ Logan, B., et al., “Identification of Synthetic Cannabinoids in ent plant species.” Forensic Science International (1999), vol. 106. Herbal Incense Blends in the United States.” Forensic Sciences, pp. 135-146. (2012), vol. 57, No. 5, pp. 1168-1180. Salamone, S., et al., “A Non-Cannabinoid Immunogen Used to De Jager, A.D. et al., “LC-MS/MS Method for the Quantitation of Elicit Antibodies with Broad Cross-Reactivity to Cannabinoid Metabolites of Eight Commonly-Used Synthetic Cannabinoids in Metabolites,” Journal of Forensic Sciences, pp. 821-826, 1998, vol. Human Urine—An Australian Perspective,” Journal of Chromatog 43, No. 4. raphy B. vol. 897, pp. 22-31, 2012. Tanaka, H., “Immunochemical Approach Using Monoclonal Anti body against 9-Tetrahydrocannabinolic Acid (THCA) to Discern * cited by examiner U.S. Patent Sep. 6, 2016 Sheet 1 of 6 US 9,435,817 B2 O H O H CH3 H3C CH3 CP 47,497 (C) O H V O H C H 3 H3C C H 3 CP 47, 497 (C) Figure 1 U.S. Patent Sep. 6, 2016 Sheet 2 of 6 US 9,435,817 B2 - Nu-99: OH CH3 H3C CH3 CP 47,497 (C7) C M O (Hap ten - 1) - Nu-0 at CH3 H3C CH3 CP 47,497 (C8) CM O (Hap ten - 2) Figure 2 U.S. Patent Sep. 6, 2016 Sheet 3 of 6 US 9,435,817 B2 Oh O OH OH PCC, DCM, RT --se Chs CH3 h3C Chs h3C Chs CP47,497 (C) 1 1N-1O COH CMO f2HC1 -eas d Pyridine CH3 3C CH Hap ten - 1 CP 47,497 (C7) CMO Figure 3a U.S. Patent Sep. 6, 2016 Sheet 4 of 6 US 9,435,817 B2 r S. ...I.,FCC, ESME, RF lY-1 S Nas -------N- Cl ---Otis C$47,497 (is) 2 sipteas 2 CP47,497 (Cs) (CMO Figure 3b U.S. Patent Sep. 6, 2016 Sheet S of 6 US 9,435,817 B2 O O n1 esuls b N 1. sus R H d Immunogen lb Tracer 1 O ---. ? aul RP CH OH Immunogen 2b Tracer 2 Figure 4 U.S. Patent Sep. 6, 2016 Sheet 6 of 6 US 9,435,817 B2 OH OH l (-)-CP 55940 l (+)- CP55940 CP 47497 para-quinone analogue Figure 5 US 9,435,817 B2 1. 2 DETECTION OF SYNTHETIC the detection of future and current JWH and CP SSCs (it CANNABINOIDS is conceivable that current herbal therapeutics, as well as CP 47,497, incorporate CPSSCs that are not yet character CROSS-REFERENCE TO RELATED ised), requires sample pre-derivatisation, specialist staff for APPLICATIONS its implementation and expensive equipment. In order to address the problem associated with the cheap and rapid The present application is a continuation-in-part of, and detection of known CP molecules and their metabolites claims priority to, U.S. application Ser. No. 13/332,042, and/or future and associated metabolites based on the CP filed Dec. 20, 2011, now issued as U.S. Pat. No. 8,906,633, drug families, the Inventors devised a novel method based which claims priority to GB Patent Applications No. 10 on novel antibodies raised from novel immunogens. The 1102544.2, filed Feb. 14, 2011, and No. 1110425.4, filed antibodies underpin an effective analytical and economic Jun. 21, 2011, all of which applications are incorporated Solution to the detection and quantification of current and herein by reference in their entireties. future CPCB-active molecules in in vitro patient samples BACKGROUND 15 and herbal therapeutics. The increasing rise in the use of stealth drugs (novel SUMMARY OF THE INVENTION synthetic drugs that were previously or remain analytically/ structurally uncharacterised and unclassified by government The invention describes a rapid and practical method for institutions), is exemplified by synthetic cannabinoid prod the detection and determination of known and/or stealth ucts which incorporate CP 47,497 as the active ingredient.